Survey of Georgia community pharmacists' needs to engage in advanced community pharmacy services.

BACKGROUND: Community pharmacists improve health, reduce fragmentation in care, lower health costs, and improve health outcomes. In Georgia, pharmacists are able to enter collaborative drug therapy management protocols, such as hypertension management, with a collaborating physician, which may allow pharmacists to provide advanced community pharmacy services (ACPS), however few Georgia pharmacists have this licensure. No program(s) exist that empower pharmacists to successfully engage in ACPS across the state of Georgia nor trains pharmacists to successfully engage in collaborative practice. OBJECTIVE: The goal of this project was to explore community pharmacists' perception, confidence, and engagement in ACPS and how this can improve access to care in Georgia. METHODS: Six hundred one independent community pharmacists were sent an electronic survey May 13, 2022, with weekly email reminders through June 17, 2022. Results were analyzed with the independent sample t test. Thematic analysis was completed on open response survey questions. RESULTS: Ninety responses were received (15% response rate). In the majority of survey outcomes, no differences were found in needs for success between rural versus urban pharmacists. Pharmacies with a smaller technician-to-pharmacists ≤2 (staffing) ratios identified billing for services as a higher priority need for success for them to confidently engage in ACPS (P = 0.012) while pharmacies with a higher technician-to-pharmacists >2 (staffing) ratio agreed a larger need was in optimization of current workflow to allow for advanced community pharmacy service incorporation (P = 0.034). All community pharmacists agreed they would require expansion in staffing and the qualities desired for additional hires to support ACPS include ambition, proficiency, and communication skills. CONCLUSION: Numerous needs for success exist for community pharmacists to feel comfortable and confident to engage in ACPS. Addressing these needs may increase community pharmacist impact through increasing utilization of these services.

Letter frequency analysis of proprietary prescription drug names in the United States: Minding the Zs and Qs.

Background: Proprietary or brand names of prescription drugs are generally with letters that are unusual in common English. There is little academic research exploring if this perception is true, despite the fact that manufacturers pay millions of dollars to research and develop drug names that conform to regulatory standards while remaining marketable. Objectives: To assess the extent to which letters used in prescription drug names may deviate from common English and to test if prescription drug names show measurable trends in letter frequency over time. Methods: The names of all prescription drugs approved in the United States between 1985 and 2020 were downloaded. Duplicates were removed and products without a proprietary name were excluded. Letter frequency analyses were then conducted on all letters in these names as an aggregate and year-over-year. Letter frequencies were compared to a validated academic reference, a corpus derived from all Google Books data, and the scoring system from the board game Scrabble. Results: Regardless of the comparator, prescription drug names use letters that are not common in typical English. Letters A (11.96% of all observed letters), V (3.08%), X (2.31%), and Z (1.91%) are all overrepresented in prescription drug names, while E (10.23%), H (0.90%), T (6.30%), and S (4.21%) are underrepresented. The letters C and N are becoming less common over time (frequency decrease of 0.10 percentage points and 0.12 percentage points per year, respectively), while V, Y, and Z are becoming more common (frequency increases of 0.61 to 0.86 percentage points per year). Conclusions: Proprietary prescription names use letters that are unlike words used in everyday American English, and there are measureable trends in letter selection. It remains to be seen how drug manufacturers will cope with an increasingly-narrow naming space as more products continue to be approved over time.